Trial Profile

Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RP-1664 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Proof of concept
Acronyms LIONS

Most Recent Events

13 Oct 2025 According to Repare Therapeutics media release, data from the trial will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
08 Aug 2025 According to Repare Therapeutics media release, data from the trial to be reported in Q4 2025.
15 Jul 2025 According to a Repare Therapeutics media release, company expects readouts from this trial in the second half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com